Anti-tumoral effect of GM-CSF with or without cytokines and monoclonal antibodies in solid tumors
- 1 September 1996
- journal article
- review article
- Published by Springer Nature in Medical Oncology
- Vol. 13 (3) , 167-176
- https://doi.org/10.1007/bf02990844
Abstract
Cytotoxicity is an important function of the immune system that results in destruction of cellular targets by humoral and cellular mechanisms. The functional capacity of granulocytes, lymphocytes and macrophages are of significance for cancer patients because of the ability of these cells to exhibit anti-tumor activity. The hallmark of immune cytotoxicity is the recognition and destruction of selected targets by humoral and cellular effects that distinguish between targets and normal cells. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a cytokine with potential to be an anti-neoplastic cytokine. GM-CSF induces: (1) differentiation of monocytes to large macrophage like cells; (2) augmentation of MHC class II antigen expression on monocytes; (3) enhancementin vitro of macrophage and granulocyte natural cytotoxicity and ADCC; and (4) increased expression of adhesion molecules on granulocytes and monocytes. GM-CSF also cooperates with other cytokines in the expansion of specific T cells. Several experimental and clinical studies have demonstrated the anti-neoplastic effects of GM-CSF alone or in combination with cytokines or/and monoclonal antibody. Interestingly, the future might see the combination of GM-CSF and mouse monoclonal antibody MAbl7-lA in the adjuvant setting in colon- and/or rectal carcinoma patients.Keywords
This publication has 67 references indexed in Scilit:
- Granulocyte-macrophage colony-stimulating factor inhibits tumor growth during the postoperative periodSurgery, 1996
- Alterations in phenotype and cell-surface antigen expression levels of human monocytes: Differential response to in vivo administration of rhm-csf or rhgm-csfCytometry, 1995
- A Phase II Trial of Concomitant Interferon-α-2b and Granulocyte–Macrophage Colony-Stimulating Factor in Patients with Advanced Renal Cell CarcinomaJournal of Immunotherapy, 1995
- Phase Ib Trial of Granulocyte-Macrophage Colony-Stimulating Factor Combined with Murine Monoclonal Antibody R24 in Patients with Metastatic MelanomaJournal of Immunotherapy, 1994
- Phase I Trial of Recombinant Granulocyte-Macrophage Colony-Stimulating Factor in Patients with Lung Cancer: Clinical and Immunologic EffectsJournal of Immunotherapy, 1993
- Cytotoxic functions of blood mononuclear cells in patients with colorectal carcinoma treated with mAb 17-1A and granulocyte/macrophage-colony-stimulating factorCancer Immunology, Immunotherapy, 1992
- Granulocyte-monocyte colony-stimulating-factor augments the interleukin-2-induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (mAb 17-1A)Cancer Immunology, Immunotherapy, 1990
- LymphokinesNew England Journal of Medicine, 1987
- The Macrophage as an Effector CellNew England Journal of Medicine, 1980
- Heterocytolysis by Macrophages Activated by Bacillus Calmette-Gurin: Lysosome Exocytosis into Tumor CellsScience, 1974